Use Of Adcc-Optimized Antibodies For Treating Weak Patients

Patent No. EP1648513 (titled "Use Of Adcc-Optimized Antibodies For Treating Weak Patients") was filed by Laboratoire Franais DU Fractionnement ET DES Biotechnologies on Jul 30, 2004. The application was issued on Sep 24, 2014.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ADAMSJun 24, 2015WILDING
KONIG SZYNKA TILMANN VON RENESSEJun 24, 2015HEMSATH

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP1648513

LABORATOIRE FRANAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Application Number
EP04786018A
Filing Date
Jul 30, 2004
Status
Revoked
Oct 2, 2021
Publication Date
Sep 24, 2014